Asset Details
Do you wish to reserve the book?
Lanreotide delays progression of neuroendocrine tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lanreotide delays progression of neuroendocrine tumours
Do you wish to request the book?
Lanreotide delays progression of neuroendocrine tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lanreotide delays progression of neuroendocrine tumours
2014
Overview
First author Martyn Caplin (Royal Free Hospital, London, UK) said, \"The CLARINET study demonstrated not only significant anti-tumour effect of lanreotide autogel in both intestinal and pancreatic NET cohorts but also demonstrated impressive results in patients with grade 2 NETs and in patients who had more than 25% of their liver replaced by tumour metastases.\"
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Female
/ Hematology, Oncology and Palliative Medicine
/ Humans
/ Intestinal Neoplasms - drug therapy
/ Intestinal Neoplasms - mortality
/ Intestinal Neoplasms - pathology
/ Male
/ Neoplasm Invasiveness - pathology
/ Neuroendocrine Tumors - drug therapy
/ Neuroendocrine Tumors - mortality
/ Neuroendocrine Tumors - pathology
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - mortality
/ Pancreatic Neoplasms - pathology
/ Peptides, Cyclic - administration & dosage
/ Somatostatin - administration & dosage
/ Somatostatin - analogs & derivatives
/ Tumors
